Abstract Session 1

Co-Chair(s)

• 

  Natalie Callander, MD

  Director, Myeloma Clinical Program
  University of Wisconsin, Wisconsin, United States
• 

  Sergio Giralt, MD

  Professor
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States

Presentations:

• 11:30 AM – 11:42 AM East Coast USA Time

  OA - 64: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial
  

  Speaker: Verónica González-Calle, MD, PhD (she/her/hers) – Department of Hematology, University Hospital of Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
• 11:42 AM – 11:54 AM East Coast USA Time

  OA – 47: Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update
  

  Speaker: Jill CORRE, PharmD, PhD (she/her/hers) – Institut Universitaire du Cancer de Toulouse-Oncopole
• 11:54 AM – 12:06 PM East Coast USA Time

  OA – 48: Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
  

  Speaker: Meletios A. Dimopoulos, MD – National and Kapodistrian University of Athens
• 12:06 PM – 12:18 PM East Coast USA Time

  OA – 50: Phase II study of iberdomide maintenance therapy post-autologous stem cell transplant in multiple myeloma: results of a planned interim analysis
  

  Speaker: Tanya Wildes, MD, MSCI (she/her/hers) – University of Nebraska Medical Center/Nebraska Medicine
• 12:18 PM – 12:30 PM East Coast USA Time

  OA – 53: Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma – 4-Year-Follow-Up from the GMMG-CONCEPT trial
  

  Speaker: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Dana-Farber Cancer Institute, Boston, MA, USA